The best in Palliative Care is summarized from:
- The Impact of Provider-Driven Serious Illness Conversations on Length of Palliative Radiotherapy for Bone Metastases
- Influence of the Pain Duration on Pain Outcomes Following Palliative Radiotherapy for Painful Tumors: The Sooner the Irradiation, the Better?
- External validation of the Bone Metastases Ensemble Trees for Survival (BMETS) machine learning model to improve estimation of life expectancy
- Classification of patients at imminent risk of death at the time of palliative radiotherapy consultation
- Phase II Clinical Trial of Stereotactic Body Radiotherapy for Painful Non-Spine Bone Metastases
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Randomized Trial
- Safety and efficacy of multi-site stereotactic body radiotherapy and pembrolizumab for patients with large, treatment-refractory tumors
- CCTG SC.24/TROG 17.06: A Randomized Phase II/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases
The course is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, learners should be able to do the following:
- Apply validated prognostication models for patients receiving palliative radiotherapy.
- Identify data justifying the use of stereotactic body radiotherapy for patients with metastatic cancer in addition to considering open questions about the use of tereotactic radiotherapy for patients with metastatic cancer.
- Describe opportunities for improving serious illness conversations for patients referred for palliative radiotherapy.
Joshua Jones, MD is employed by University of Pennsylvania and has no other disclosures to declare.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.